Trial Profile
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin/metformin (Primary) ; Saxagliptin (Primary) ; Glimepiride; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Oct 2023 Status changed from not yet recruiting to completed, according to results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
- 06 Oct 2023 Primary endpoint (Proportion of patients who met HbA1c 6.5% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 104 weeks) has been met, according to results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
- 06 Oct 2023 Results ( n= 105) evaluating the efficacy and tolerability of an initial triple combination with metformin, dapagliflozin and saxagliptin compared with conventional stepwise add-on therapy in drug-naive patients with type 2 diabetes presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.